HeartSciences Inc. (HSCS) stock: key figures, P/E, revenue and dividend

Financials · United States · ISIN US42254E3027

Price
2.13 USD
Market cap
10.20 m USD
P/E (2026)
–
P/S (2026)
2,361.74
Dividend yield
0.00 %
Net margin
-211,666.47 %
Return on equity (ROE)
-4,044.00 %
Return on assets (ROA)
-173.71 %

HeartSciences Inc. financials

Fiscal year20252026
Revenue4,350.00 USD4,319.00 USD
Gross profit2,470.00 USD2,551.00 USD
Operating income-8.35 m USD-8.41 m USD
EBIT-8.26 m USD-8.39 m USD
Net income-8.77 m USD-9.14 m USD
Diluted EPS – continuing operations-9.34 USD–

Full history since 2020, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About HeartSciences Inc.

HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic ECG management platform. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.